DUBLIN–(BUSINESS WIRE)–The “Low Back Pain – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Low Back Pain – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 12, 9, 3, 2 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. (Read more…)
- The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)
Key Topics Covered:
- Introduction
- Low Back Pain – Overview
- Low Back Pain – Therapeutics Development
- Low Back Pain – Therapeutics Assessment
- Low Back Pain – Companies Involved in Therapeutics Development
- Low Back Pain – Drug Profiles
- Low Back Pain – Dormant Projects
- Low Back Pain – Discontinued Products
- Low Back Pain – Product Development Milestones
- Appendix
Companies Mentioned
- Ache Laboratorios Farmaceuticos SA
- Adynxx Inc
- Allodynic Therapeutics LLC
- Amplicore Inc
- AnGes Inc
- Axsome Therapeutics Inc
- BioRestorative Therapies Inc
- Bol Pharma
- Camurus AB
- Causeway Therapeutics Ltd
- Creative Medical Technology Holdings Inc
- Daewon Pharmaceutical Co Ltd
- Eli Lilly and Co
- Evero Health Ltd
- Frontier Biotechnologies Inc
- Gador SA
- Grunenthal GmbH
- Hisamitsu Pharmaceutical Co Inc
- Imbrium Therapeutics LP
- Immune Pharmaceuticals Inc
- Inspyr Therapeutics Inc
- Intec Pharma Ltd
- MD Biosciences GmbH
- Mesoblast Ltd
- Navipharm Co Ltd
- Persica Pharmaceuticals Ltd
- Pfizer Inc
- Qingdao Chia Tai Haier Pharmaceutical Co Ltd
- Scilex Holding Co
- Stayble Therapeutics AB
- Sun Pharma Advanced Research Company Ltd
- WEX Pharmaceuticals Inc
- Xgene Pharmaceutical Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/t1zwwe
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900